• Skip to primary navigation
  • Skip to content
  • Skip to footer
CardioCell

CardioCell

Breakthrough Cardiovascular Technology

  • About Us
    • Overview
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Our Stem Cells
    • Manufacturing
    • Quality Control
    • Exclusive License
  • Clinical Trials
    • Overview
    • Chronic Heart Failure
    • Heart Failure in Patients With Left Ventricular Assist Devices
    • Acute Myocardial Infarction
  • News
    • Press Releases
    • Media Coverage
    • Publications
  • Events
  • LinkedIn

Media Coverage

June 20, 2014

Stemedica plans to initiate Phase IIa 70-patient Alzheimer’s disease trial this year – executive

News Jun 20, 2014 Stemedica plans to initiate Phase IIa 70-patient Alzheimer’s disease trial this year – executive Another Stemedica subsidiary, CardioCell, has an exclusive, worldwide license for IV-administered allogeneic ischemia-tolerant mesenchymal stem cells (itMSCs).

Read More

Media Coverage

April 5, 2014

Stem cell trial is approved for patients with heart failure

News Apr 5, 2014 Stem cell trial is approved for patients with heart failure CardioCell has received approval from the FDA for a Phase IIa clinical trial of its allogeneic stem cell therapy for chronic heart failure. READ FULL ARTICLE

Read More

Media Coverage

April 4, 2014

FDA Approves CardioCell’s Phase 2A Trial For CHF Stem Cell Therapy

News Apr 4, 2014 FDA Approves CardioCell's Phase 2A Trial For CHF Stem Cell Therapy CardioCell LLC announced that it has received FDA approval for its investigational new drug (IND) application for a U.S.-based Phase IIA clinical study evaluating its allogeneic stem-cell therapy for

Read More

Media Coverage

April 4, 2014

CardioCell to scout for CROs for PAD trial with allogeneic mesenchymal stem cells, in partnership talks – CEO

News Apr 4, 2014 CardioCell to scout for CROs for PAD trial with allogeneic mesenchymal stem cells, in partnership talks –

Read More

Media Coverage

April 3, 2014

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

News Apr 3, 2014 CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell

Read More

Media Coverage

April 2, 2014

FDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial

News Apr 2, 2014 FDA grants IND approval for CardioCell’s phase IIa itMSC Therapy trial CardioCell, a global biotechnology company, has just received the FDA’s Investigational New Drug (IND) approval for a U.S.-based, phase IIa clinical study using its allogeneic stem-cell therapy to

Read More

Media Coverage

April 2, 2014

FDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy

News Apr 2, 2014 FFDA Gives Go-Ahead for Phase 2a Trial of CardioCell CHF Stem Cell Therapy CardioCell LLC has just received the FDA’s investigational new drug (IND) approval for a United States-based, Phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects

Read More

Media Coverage

April 2, 2014

CardioCell gets IND approval from FDA

News Apr 2, 2014 CardioCell gets IND approval from FDA San Diego-based CardioCell LLC on Wednesday received the Food and Drug Administration’s investigational new drug (IND) approval for a phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects with chronic

Read More

Media Coverage

  • « Previous Page
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Page »

Footer

About Us

  • Overview
  • Board of Directors
  • Scientific Advisory Board

Technology

  • Our Stem Cells
  • Manufacturing
  • Quality Control
  • Exclusive License

Clinical Trials

  • Overview
  • Chronic Heart Failure
  • Heart Failure in Patients With Left Ventricular Assist Devices
  • Acute Myocardial Infarction
<section id="bpfwp_contact_card_widget-1" class="widget widget_bpfwp_contact_card_widget"><div class="widget-wrap"><h3 class="widgettitle widget-title">Contact</h3>
info@stemcardiocell.com
</div></section>

Copyright © 2023 · Business Pro Theme on Genesis Framework · WordPress · Log in